Could Phaxan™ become the new drug of choice for intravenous anaesthesia, procedural and intensive care sedation.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Could Phaxan™ become the new drug of choice for intravenous anaesthesia, procedural and intensive care sedation.
Released on: November 28, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    The need for a for a new anaesthetic that is both safe and effective continues to grow significantly, with more than 80 million general anaesthesia procedures performed annually in the United States and Europe alone.
  • Summary
  • Transcript
  • Participants
  • Company
The need for a for a new anaesthetic that is both safe and effective continues to grow significantly, with more than 80 million general anaesthesia procedures performed annually in the United States and Europe alone. Since Drawbridge Pharmaceuticals was founded in 2011, it has been building a robust patent portfolio around its lead drug candidate, Phaxan™, for global use in anaesthesia and sedation. During AusBiotech 2014 PharmaVentures' Fintan Walton caught up with Drawbridge CEO, Anthony Filippis to find out why Phaxan has the potential to become the new gold standard drug of choice for intravenous anaesthesia.
The anaesthesia drugs market in the US is forecast to reach $7 billion by 2015. The need for a for a new anaesthetic that is both safe and effective continues to grow significantly, with more than 80 million general anaesthesia procedures performed annually in the United States and Europe alone. Since Drawbridge Pharmaceuticals was founded in 2011, it has been building a robust patent portfolio around its lead drug candidate, Phaxan™, for global use in anaesthesia and sedation. During AusBiotech 2014 PharmaVentures' Fintan Walton caught up with Drawbridge CEO, Anthony Filippis to find out why Phaxan has the potential to become the new gold standard drug of choice for intravenous anaesthesia.
Anthony Filippis

Dr Anthony Filippis PhD MBA Anthony Filippis is an innovative biotechnology business executive and entrepreneur with more than 15 years experience in the industry. Anthony is a Founder of Senz Oncology, an oncology drug development company and Afandin Pty Ltd, a technology-focussed corporate advisory company, specialising in the biotechnology, pharmaceutical and life sciences industries. Prior to joining Drawbridge in July 2012, Anthony held senior executive management positions at Xenome, Meditech Research/Alchemia Oncology, Metabolic Pharmaceuticals, Select Vaccines and Premier Bionics, where he completed a number of M&A, in- and out-licensing and capital raising deals. Anthony holds a PhD in biochemistry from the University of Melbourne, an MBA from LaTrobe University.
Drawbridge Pharmaceuticals was founded in 2011. It is a privately-held company headquartered in Melbourne, Australia. Drawbridge is developing neuroactive steroid compounds for use in critical care situations in which protection of the brain from insult is required. Phaxan™ is the lead compound for use as a fast onset and offset intravenous general anaesthetic and sedative that causes neuroprotection. Phaxan™ is a novel water based formulation of the neuroactive steroid, alphaxalone. It has a wide therapeutic index and rapid onset and offset of action. The anaesthetic agent in Phaxan™ has been administered in the past as Althesin® when formulated in a different excipient. It was withdrawn in 1984 because of problems with the formulation. Phaxan™ does not have the problems of the Althesin® formulation and is superior to propofol in preclinical models. Phaxan™ is a registered trade mark for alphaxalone formulated in sulfobutyl ether beta cyclodextrin being developed by Drawbridge Pharmaceuticals.